Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapsone maintenance therapy versus placebo for cutaneous leukocytoclastic vasculitis
2005-001245-41Phase 3Terminated
- Sponsor
- Department of Dermatology, Medical University of Graz
- Start
- Aug 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cutaneous vasculitis (CSVV) and cutaneous leukocytoclastic vasculitis (LCV) comparing Dapsone with Placebo (2 arms). Primary endpoint: Marked responder rate at week 4. Started Aug 2005; status: terminated.
02
Drugs
dapsone
03
Conditions
cutaneous vasculitis (CSVV)cutaneous leukocytoclastic vasculitis (LCV)
Beyond the preview
Go deeper on 2005-001245-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001245-41.